10-day decitabine versus conventional chemotherapy (“3+7”) followed by allografting in AML patients ≥ 60 years: Long-term follow-up results of the randomized phase III trial AML21 of the EORTC leukemia group, GIMEMA and german MDS Study group
Randomized trial revealed comparable overall survival in AML patients, suggesting decitabine may improve safety and quality of life.
Key Points
Overall survival was similar between decitabine and chemotherapy groups, with lower adverse events observed in the decitabine cohort.
Long-term follow-up of 606 patients showed median follow-up of 5.8 years, with 23.7% survivors in the decitabine group at six years.
Randomized controlled trial design provided robust insights into efficacy, leading to further examination of progression-free survival and health-related quality of life.
This work highlights the potential for decitabine to offer a safer alternative when bridging to allogeneic HSCT in older AML patients.